Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07750041
Starting soon Phase 1/2

A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer

NCT07750041 · tracked via the Priya Life Science China tracker
Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd
Phase
Phase 1/2
Started
2026-08-30
Last updated
2026-08-06

Condition(s) studied

Unresectable Advanced or Metastatic Colorectal Cancer

Investigational drug(s) / intervention(s)

SYS6090 (Fixed Dose Level A) + bevacizumabAll SYS6090 trials (2) →All Bevacizumab trials (435) →SYS6090 (Fixed Dose Level B ) + bevacizumabAll SYS6090 trials (2) →All Bevacizumab trials (435) →SYS6090 RP2D + bevacizumab +mFOLFOX6All Bevacizumab trials (435) →All MFOLFOX6 trials (35) →SYS6090 RP2D + bevacizumab →Regorafenib →SYS6090 PR2D+ bevacizumab + FOLFOXIRIAll Bevacizumab trials (435) →All Folfoxiri trials (9) →bevacizumab + FOLFOXIRIAll Bevacizumab trials (435) →All Folfoxiri trials (9) →

SYS6090 (Fixed Dose Level A) + bevacizumab: Participants will receive intravenous SYS6090 at fixed dose level A combined with intravenous bevacizumab, administered per cycle schedule specified in study protocol, for advanced/palliative unresectable pMMR/MSS colorectal cancer.

SYS6090 (Fixed Dose Level B ) + bevacizumab: Participants will receive intravenous SYS6090 at fixed dose level B plus intravenous bevacizumab per protocol-defined cycle schedule for unresectable advanced pMMR/MSS colorectal cancer.

SYS6090 RP2D + bevacizumab +mFOLFOX6: Participants will receive intravenous SYS6090 at RP2D plus intravenous bevacizumab combined with standard mFOLFOX6 chemotherapy regimen (oxaliplatin, leucovorin, fluorouracil), administered per protocol-defined cycle schedule for unresectable advanced pMMR/MSS colorectal cancer.

SYS6090 RP2D + bevacizumab: Participants will receive intravenous SYS6090 at RP2D plus intravenous bevacizumab, administered per protocol-defined cycle schedule for unresectable advanced pMMR/MSS colorectal cancer.

Regorafenib: Oral regorafenib monotherapy as standard control for metastatic pMMR/MSS colorectal cancer.

SYS6090 PR2D+ bevacizumab + FOLFOXIRI: Participants will receive intravenous SYS6090at RP2D plus intravenous bevacizumab combined with FOLFOXIRI triple chemotherapy (oxaliplatin, irinotecan, leucovorin, fluorouracil) per study cycle schedule for metastatic pMMR/MSS colorectal cancer.

bevacizumab + FOLFOXIRI: Participants will receive intravenous bevacizumab combined with FOLFOXIRI triple chemotherapy (oxaliplatin, irinotecan, leucovorin, fluorouracil) per study cycle schedule for metastatic pMMR/MSS colorectal cancer.

Study summary

This study constitutes an open-label, multi-cohort, multi-center Phase Ib/II clinical study, developed to assess the safety, tolerability, and therapeutic efficacy of SYS6090 injection when administered in combination with bevacizumab, or in triple combination with bevacizumab and chemotherapy, among patients diagnosed with advanced colorectal cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
\*Eligibility Criteria: Inclusion Criteria: 1. Subjects must be ≥18 years of age. 2. Histologically or cytologically confirmed unresectable advanced or metastatic colorectal cancer with pMMR/MSS status, assigned to corresponding cohorts as follows: Cohort 1 (2L/3L) of Phase Ib \& Phase II: Subjects must have disease progression after no more than 2 lines of standard systemic therapy (prior regimens must contain fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy); tumor tissue confirmed as pMMR by IHC or MSS by NGS/PCR; Cohort 2 (1L) of Phase Ib \& Phase II: Subjects have received no prior systemic anti-tumor therapy for advanced disease; tumor tissue confirmed as pMMR by IHC or MSS by NGS/PCR. 3. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria. 4. Eastern Cooperative Oncology Group performance status of 0 or 1. 5. Expected survival ≥ 3 months. 6. Has protocol-defined adequate organ and bone marrow function. Exclusion Criteria: 1. Subjects with clinically active central nervous system metastases; 2. with a history of other primary malignant tumors within 5 years before administration; 3. Subjects assigned to Cohort 1 who have received prior regorafenib treatment.; 4. Prior documented interstitial lung disease (ILD)/ pneumonitis that required steroids, current ILD/ pneumonitis, or suspected ILD/ pneumonitis that cannot be ruled out by imaging at screening; 5. Uncontrolled or significant cardiovascular disease; 6. Clinically uncontrolled pleural effusion, ascites or pericardial effusion; 7. Has unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to Grade ≤ 1 or baseline .

Primary outcome measure(s)

  • Recommended Phase 2 Dose (RP2D), Safety and Tolerability — up to approximately 3 years after the first enrollment
    RP2D of SYS6090 combination therapy,Safety and tolerability are evaluated via incidence and severity of all Adverse Events (AEs) and Serious Adverse Events (SAEs) graded per NCI-CTCAE version 6.0, including abnormal laboratory tests, ECG parameters and vital signs from screening through end of safety follow-up.
  • Objective Response Rate (ORR) assessed per RECIST v1.1 — up to approximately 3 years after the first enrollment
    ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by investigator was defined as the percentage of participants with at least one visit confirmed complete response (CR) or partial response (PR), for all cohorts in Phase Ib and Cohort 1 of Phase II expansion stage.
  • Progression-Free Survival (PFS) assessed per RECIST v1.1 — up to approximately 3 years after the first enrollment
    PFS per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by investigator was defined as the time from the date of randomization or first study treatment until the date of confirmed progressive disease (PD), or death by any cause in the absence of progression, regardless of whether the participant withdrew from study therapy or received another anticancer therapy prior to progression, for Cohort 2 of Phase II expansion stage.

Trial sites (1)

FacilityCityRegionStatus
Fujian Cancer Hospital Fujian Fuzhou

On this site

📄 Stivarga (regorafenib) drug profile →

More CSPC Megalith Biopharmaceutical Co.,Ltd. trials in China

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors Active, not recruiting
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor Recruiting
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） Recruiting
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors Recruiting
A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07750041 on ClinicalTrials.gov ↗ ← All trials in China